TY - JOUR T1 - Zinc oxide nanoparticles as selective killers of proliferating cells A1 - Taccola,Liuba A1 - Raffa,Vittoria A1 - Riggio,Cristina A1 - Vittorio,Orazio A1 - Iorio,Maria Carla A1 - Vanacore,Renato A1 - Pietrabissa,Andrea A1 - Cuschieri,Alfred AU - Taccola,Liuba AU - Raffa,Vittoria AU - Riggio,Cristina AU - Vittorio,Orazio AU - Iorio,Maria Carla AU - Vanacore,Renato AU - Pietrabissa,Andrea AU - Cuschieri,Alfred PY - 2011/5 Y1 - 2011/5 N2 -
Background: It has recently been demonstrated that zinc oxide nanoparticles (ZnO NPs) induce death of cancerous cells whilst having no cytotoxic effect on normal cells. However, there are several issues which need to be resolved before translation of zinc oxide nanoparticles into medical use, including lack of suitable biocompatible dispersion protocols and a better understanding being needed of the mechanism of their selective cytotoxic action.
Methods: Nanoparticle dose affecting cell viability was evaluated in a model of proliferating cells both experimentally and mathematically. The key issue of selective toxicity of ZnO NPs toward proliferating cells was addressed by experiments using a biological model of noncancerous cells, ie, mesenchymal stem cells before and after cell differentiation to the osteogenic lineage.
Results: In this paper, we report a biocompatible protocol for preparation of stable aqueous solutions of monodispersed zinc oxide nanoparticles. We found that the threshold of intracellular ZnO NP concentration required to induce cell death in proliferating cells is 0.4 +/- 0.02 mM. Finally, flow cytometry analysis revealed that the threshold dose of zinc oxide nanoparticles was lethal to proliferating pluripotent mesenchymal stem cells but exhibited negligible cytotoxic effects to osteogenically differentiated mesenchymal stem cells.
Conclusion: Results confirm the ZnO NP selective cytotoxic action on rapidly proliferating cells, whether benign or malignant.
AB -Background: It has recently been demonstrated that zinc oxide nanoparticles (ZnO NPs) induce death of cancerous cells whilst having no cytotoxic effect on normal cells. However, there are several issues which need to be resolved before translation of zinc oxide nanoparticles into medical use, including lack of suitable biocompatible dispersion protocols and a better understanding being needed of the mechanism of their selective cytotoxic action.
Methods: Nanoparticle dose affecting cell viability was evaluated in a model of proliferating cells both experimentally and mathematically. The key issue of selective toxicity of ZnO NPs toward proliferating cells was addressed by experiments using a biological model of noncancerous cells, ie, mesenchymal stem cells before and after cell differentiation to the osteogenic lineage.
Results: In this paper, we report a biocompatible protocol for preparation of stable aqueous solutions of monodispersed zinc oxide nanoparticles. We found that the threshold of intracellular ZnO NP concentration required to induce cell death in proliferating cells is 0.4 +/- 0.02 mM. Finally, flow cytometry analysis revealed that the threshold dose of zinc oxide nanoparticles was lethal to proliferating pluripotent mesenchymal stem cells but exhibited negligible cytotoxic effects to osteogenically differentiated mesenchymal stem cells.
Conclusion: Results confirm the ZnO NP selective cytotoxic action on rapidly proliferating cells, whether benign or malignant.
KW - zinc oxide nanoparticles KW - dispersion KW - selective cytotoxicity KW - mesenchymal stem cells KW - ZNO NANOPARTICLES KW - OPTICAL-PROPERTIES KW - NANOSTRUCTURES KW - INDUCTION KW - MECHANISM KW - AUTOPHAGY KW - TOXICITY KW - BACTERIA KW - MARROW U2 - 10.2147/IJN.S16581 DO - 10.2147/IJN.S16581 M1 - Article JO - International Journal of Nanomedicine JF - International Journal of Nanomedicine SN - 1178-2013 VL - 6 SP - 1129 EP - 1140 ER -